| 1 | Polypeptide hormones, protein hormones and glycoprotein hormones, their derivatives and structural analogues: other than somatotropin, (its derivatives and structural anaologues) and insulin and its saltsHS6 293719 - six-digit product code | $16.4B | 0% | 2.1 | High attention |
|---|
| 2 | Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail saleHS6 300215 - six-digit product code | $67.6B | 0% | 0.9 | Stable |
|---|
| 3 | Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, mixed, put up in measured doses or in forms or packings for retail saleHS6 300214 - six-digit product code | $15.4B | 0% | 1.3 | High attention |
|---|
| 4 | Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail saleHS6 300490 - six-digit product code | $76.8B | 17.7% | 0.6 | Stable |
|---|
| 5 | Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereofHS6 293359 - six-digit product code | $8.3B | 0% | 1 | High attention |
|---|
| 6 | Vaccines: for human medicineHS6 300220 - six-digit product code | $11.3B | 0% | 1.4 | High attention |
|---|
| 7 | Odoriferous substances and mixtures: of a kind used in the food or drink industriesHS6 330210 - six-digit product code | $4.4B | 0% | 0.7 | High attention |
|---|
| 8 | Medical, surgical instruments and appliances: catheters, cannulae and the likeHS6 901839 - six-digit product code | $10.2B | 13.1% | 0.7 | Stable |
|---|
| 9 | Artificial parts of the bodyHS6 902131 - six-digit product code | $3.3B | 0% | 1 | High attention |
|---|
| 10 | Medical, surgical or dental instruments and appliances: n.e.c. in heading no. 9018HS6 901890 - six-digit product code | $19.2B | 0% | 0.8 | Stable |
|---|